登入
選單
返回
Google圖書搜尋
Assessment of Retinopathy of Prematurity Regression and Reactivation Using an Artificial Intelligence–based Vascular Severity Score
Sonja K. Eilts
Wolf A. Lagrèze
J. Peter Campbell
Andreas Stahl
Anima Désirée Bühler
Moritz Claudius Daniel
Susanne Felzmann
Nikolai Gross
Stefanie Horn
Fanni E. Molnar
Claudia Müller
Sabine Reichl
Charlotte M. Reiff
Olga Richter
Milena Stech
Roland Hentschel
Dimitria Stavropolou
Juliane Tautz
出版
Universität
, 2023
URL
http://books.google.com.hk/books?id=OzTJzwEACAAJ&hl=&source=gbs_api
註釋
Abstract: Importance One of the biggest challenges when using anti-vascular endothelial growth factor (VEGF) agents to treat retinopathy of prematurity (ROP) is the need to perform long-term follow-up examinations to identify eyes at risk of ROP reactivation requiring retreatment.
Objective To evaluate whether an artificial intelligence (AI)-based vascular severity score (VSS) can be used to analyze ROP regression and reactivation after anti-VEGF treatment and potentially identify eyes at risk of ROP reactivation requiring retreatment.
Design, Setting, and Participants This prognostic study was a secondary analysis of posterior pole fundus images collected during the multicenter, double-blind, investigator-initiated Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) randomized clinical trial, which compared 2 different doses of ranibizumab (0.12 mg vs 0.20 mg) for the treatment of ROP. The CARE-ROP trial screened and enrolled infants between September 5, 2014, and July 14, 2016. A total of 1046 wide-angle fundus images obtained from 19 infants at predefined study time points were analyzed. The analyses of VSS were performed between January 20, 2021, and November 18, 2022.
Interventions An AI-based algorithm assigned a VSS between 1 (normal) and 9 (most severe) to fundus images.
Main Outcomes and Measures Analysis of VSS in infants with ROP over time and VSS comparisons between the 2 treatment groups (0.12 mg vs 0.20 mg of ranibizumab) and between infants who did and did not receive retreatment for ROP reactivation.
Results Among 19 infants with ROP in the CARE-ROP randomized clinical trial, the median (range) postmenstrual age at first treatment was 36.4 (34.7-39.7) weeks; 10 infants (52.6%) were male, and 18 (94.7%) were White. The mean (SD) VSS was 6.7 (1.9) at baseline and significantly decreased to 2.7 (1.9) at week 1 (P .001) and 2.9 (1.3) at week 4 (P .001). The mean (SD) VSS of infants with ROP reactivation requiring retreatment was 6.5 (1.9) at the time of retreatment, which was significantly higher than the VSS at week 4 (P
